BPC-157 and Bone Healing: Fracture Repair Research
BPC-157 Musculoskeletal
Comparable to bone grafts
In a rabbit segmental bone defect model, BPC-157 produced healing equivalent to autologous bone marrow and cortical bone grafts.
Sebecic et al., Bone, 1999
Sebecic et al., Bone, 1999
View as imageA rabbit with an 0.8 cm hole drilled through its radius bone received daily injections of a 15-amino-acid peptide derived from human gastric juice. Six weeks later, that hole had formed complete bony continuity across the defect site. The control animals, receiving saline, never healed.[1]
That 1999 study remains the most direct evidence that BPC-157 can promote bone regeneration. It sits within a broader body of preclinical research showing this peptide accelerates healing in tendons, ligaments, and muscle. But bone healing is mechanistically distinct from soft tissue repair, and the evidence base here is thinner than many online sources suggest.
This article examines every published study connecting BPC-157 to bone healing, the proposed molecular mechanisms, and the substantial gaps that remain before these animal findings could inform clinical practice.
Key Takeaways
- BPC-157 healed segmental bone defects in rabbits with osteogenic activity comparable to autologous bone marrow grafts and cortical bone implants (Sebecic et al., 1999)
- The peptide activates VEGFR2-Akt-eNOS signaling to promote angiogenesis, a process critical to fracture repair (Hsieh et al., 2017)
- BPC-157 reduced alveolar bone loss by 40-60% in a rat periodontitis model through anti-inflammatory mechanisms (Keremi et al., 2009)
- Growth hormone receptor expression increased dose-dependently in fibroblasts treated with BPC-157, potentially amplifying the anabolic healing response (Chang et al., 2014)
- A 2025 systematic review of 544 articles found 36 relevant studies (35 preclinical, 1 clinical), with zero human bone healing data (Vasireddi et al., 2025)
- The only human musculoskeletal study involved 16 knee pain patients, none with fractures (Lee and Padgett, 2021)
How bones heal and where BPC-157 might intervene
Fracture repair proceeds through three overlapping phases: inflammation, repair, and remodeling. Understanding these phases clarifies where a pro-angiogenic, anti-inflammatory peptide could theoretically accelerate the process.
Inflammation (hours to days). When bone breaks, blood vessels rupture and form a fibrin-rich hematoma around the fracture site. Within 24-48 hours, inflammatory cytokines (TNF-alpha, IL-1, IL-6) recruit macrophages and monocytes. These cells clear necrotic tissue and secrete vascular endothelial growth factor (VEGF), which initiates the formation of new blood vessels. This inflammatory phase is not just cleanup; it is the trigger for the entire healing cascade. Disrupting it delays healing. Prolonging it also delays healing. The timing matters.
Repair (days to weeks). Mesenchymal stem cells migrate to the fracture site and differentiate into chondroblasts and osteoblasts. Chondroblasts lay down a fibrocartilage matrix (soft callus) that bridges the fracture gap. Osteoblasts then mineralize this scaffold into woven bone (hard callus). Throughout this phase, angiogenesis is the rate-limiting step. Without new blood vessels delivering oxygen and progenitor cells, the soft callus cannot mineralize. Fractures that fail to develop adequate blood supply become delayed unions or nonunions.
Remodeling (weeks to years). Osteoclasts resorb woven bone while osteoblasts deposit organized lamellar bone in its place. This process can continue for months to years until the bone regains its original architecture and mechanical strength.
BPC-157's documented effects touch multiple points in this cascade. The peptide promotes angiogenesis through VEGFR2 signaling,[2] reduces inflammatory cytokine activity,[3] and upregulates growth hormone receptor expression in fibroblasts.[4] Each of these could theoretically accelerate fracture repair, particularly by addressing the angiogenesis bottleneck during the repair phase. Whether they actually do in intact human bone remains an open question.
The rabbit segmental bone defect study
The cornerstone of the BPC-157 bone healing evidence is Sebecic et al. (1999), published in Bone.[1]
Researchers created a 0.8 cm osteoperiosteal defect in the middle of the left radius in rabbits. This defect was large enough that control animals never achieved healing over the 6-week observation period. BPC-157 was tested through multiple administration routes:
- Local injection into the bone defect (10 microg/kg)
- Intermittent intramuscular injection at days 7, 9, 14, and 16 (10 microg/kg)
- Continuous intramuscular injection daily from days 7-21 (10 microg/kg or 10 ng/kg)
For comparison, one group received autologous bone marrow injected into the defect, and another received a cortical bone graft placed immediately after surgery.
The results showed BPC-157 at 10 microg/kg given intramuscularly for 14 days produced healing comparable to both bone marrow and cortical graft transplantation, as assessed by radiographic callus surface area, microphotodensitometry, and quantitative histomorphometry. Even at the 1,000-fold lower dose of 10 ng/kg, the peptide showed comparable histomorphometric improvement.
All control animals still had unhealed defects at 6 weeks. Animals receiving BPC-157 through any administration route showed increased rates of complete bony continuity across the defect.
The study framed these findings in the context of gastrectomy-related osteoporosis. Patients who undergo stomach removal develop bone loss at higher rates, a phenomenon called postgastrectomy bone disease. This clinical observation suggests the stomach normally produces factors that support bone homeostasis. BPC-157, isolated from a protein found in human gastric juice, may represent one such factor. If true, this would connect gut-bone signaling in a way that parallels recent research on the gut-brain axis and gut-immune axis.
The dose-response findings are unusual and deserve scrutiny. BPC-157 showed histomorphometric improvement at both 10 microg/kg and 10 ng/kg, doses separated by three orders of magnitude. Most pharmacological agents show a clear dose-response curve. The absence of one here could indicate a threshold effect, a saturated receptor system, or limitations in the histomorphometric measurement. The study did not report quantitative dose-response data for the lower dose beyond the histomorphometry comparison.
Limitations are substantial. The study used a single species (rabbit), a single defect model (segmental osteoperiosteal defect of the radius), and came from the same Zagreb research group (led by Predrag Sikiric) that has produced the majority of BPC-157 literature. No independent laboratory has attempted to replicate these bone findings. The study did not include sham-operated controls (only saline-treated injured animals), and blinding procedures were not described. Sample sizes per group were not clearly reported in the abstract.
Molecular mechanisms: VEGFR2, nitric oxide, and ERK1/2
Three studies illuminate how BPC-157 might promote bone healing at the molecular level.
VEGFR2-Akt-eNOS pathway
Hsieh et al. (2017) demonstrated that BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) expression in human endothelial cells and activates the VEGFR2-Akt-eNOS signaling cascade.[2] In a rat hind limb ischemia model, BPC-157 accelerated blood flow recovery and increased vessel density. Histological analysis confirmed enhanced vascular expression of VEGFR2 in treated tissue.
This matters for bone because angiogenesis is a rate-limiting step in fracture repair. New blood vessels deliver oxygen, nutrients, and progenitor cells to the fracture site. Without adequate vascularization, fractures develop delayed union or nonunion. BPC-157's ability to promote vessel formation through VEGFR2 provides a plausible mechanism for its bone healing effects.
The peptide also works through a VEGF-independent route. BPC-157 activates the Src-caveolin-1-eNOS pathway, generating nitric oxide that promotes vasodilation and vascular stability.[2]
ERK1/2 signaling
Huang et al. (2015) showed BPC-157 activates extracellular signal-regulated kinases 1 and 2 (ERK1/2) in human endothelial cells, along with downstream targets c-Fos, c-Jun, and Egr-1.[5] In an alkali-burn wound model, this translated to faster granulation tissue formation, re-epithelialization, and collagen deposition. ERK1/2 signaling is also central to osteoblast differentiation and proliferation, though BPC-157's direct effect on ERK1/2 in bone cells has not been tested.
Growth hormone receptor upregulation
Chang et al. (2014) used cDNA microarray analysis to identify growth hormone receptor (GHR) as one of the most abundantly upregulated genes in tendon fibroblasts treated with BPC-157.[4] BPC-157 dose- and time-dependently increased GHR expression at both mRNA and protein levels. When growth hormone was added to BPC-157-treated cells, proliferation increased through JAK2 activation.
Growth hormone plays a well-established role in bone formation and remodeling. If BPC-157 sensitizes bone cells to growth hormone the way it sensitizes tendon fibroblasts, this could amplify the anabolic response during fracture repair. This hypothesis has not been directly tested in osteoblasts or bone tissue.
Beyond fractures: tendon-to-bone and alveolar bone
Two additional studies extend BPC-157's bone-related effects beyond fracture models.
Achilles tendon-to-bone healing
Krivic et al. (2006) sharply transected the rat Achilles tendon from the calcaneal bone, creating a model where tendon-to-bone healing does not occur spontaneously.[6] BPC-157 (10 microg, 10 ng, or 10 pg per kg body weight, IP daily) improved healing across every measured outcome:
- Functional: Achilles functional index values substantially increased
- Biomechanical: load to failure, stiffness, and Young's elasticity modulus all increased
- Histological: better organization of collagen fibers, advanced vascular appearance, more collagen type I
BPC-157 also opposed the healing aggravation caused by methylprednisolone, a corticosteroid commonly used in orthopedic practice. This finding has relevance for patients who need both fracture healing and steroid therapy.
Alveolar bone resorption in periodontitis
Keremi et al. (2009) tested BPC-157 in a ligature-induced periodontitis model in rats.[7] Silk ligature placement around the lower first molar produced inflammation, tissue damage, and alveolar bone destruction over 12 days. BPC-157 given systemically (once daily) reduced Evans blue plasma extravasation (a measure of inflammation), histological signs of tissue damage, and alveolar bone resorption as measured by micro-CT.
This is the only study directly measuring BPC-157's effect on bone resorption (as opposed to bone formation). The finding that BPC-157 reduced bone loss through anti-inflammatory mechanisms suggests the peptide may protect bone indirectly, by dampening the inflammatory cascade that drives osteoclast activity.
The 2025 systematic review
Vasireddi et al. (2025) conducted the most comprehensive review of BPC-157 in orthopedic sports medicine to date, published in the HSS Journal.[8] Starting with 544 articles published from 1993 to 2024, they screened down to 36 studies that met inclusion criteria: 35 preclinical and 1 clinical.
Key findings relevant to bone:
- BPC-157 improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injury models
- The peptide enhances growth hormone receptor expression and pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines
- BPC-157 is metabolized in the liver with a half-life under 30 minutes and cleared by the kidneys
- No adverse effects were found across preclinical safety studies
- No clinical safety data exist
The review classified all included studies as Level IV or Level V evidence (case series and expert opinion). The authors specifically noted the "absence of randomized controlled trials or large prospective cohort studies."
The evidence gap: zero human bone healing data
The single human musculoskeletal study in the literature is Lee and Padgett (2021), a retrospective chart review of 17 patients (16 contacted for follow-up) who received intra-articular BPC-157 injections for chronic knee pain.[9] Among the 12 patients receiving BPC-157 alone, 11 (91.6%) reported significant pain improvement at 6-12 month follow-up.
This study has no relevance to bone fracture healing. The patients had osteoarthritis, meniscus tears, tendinosis, and ligament injuries. No fractures. No imaging to document structural changes. No control group. No validated outcome measures.
The gap between the animal evidence and clinical application involves several specific problems:
Single research group dominance. The vast majority of BPC-157 literature comes from Sikiric and colleagues at the University of Zagreb. The bone healing study (Sebecic 1999) includes Sikiric as a co-author. Independent replication of bone-specific effects has not occurred.
Species translation uncertainty. Rabbit bone healing differs from human bone healing in vascularity, remodeling rate, and biomechanical loading. The segmental defect model, while useful, does not represent the most common human fracture patterns.
Dose and delivery unknowns. The Sebecic study showed effectiveness at both 10 microg/kg and 10 ng/kg (a 1,000-fold range), which is unusual and raises questions about dose-response relationships. Optimal timing, duration, and route of administration for human fractures are completely undefined.
Regulatory status. BPC-157 lacks FDA approval for any indication. The World Anti-Doping Agency banned it in 2022. The FDA classified it as Category 2, restricting compounding pharmacies from manufacturing it.
No mechanism-of-action studies in bone cells. While BPC-157's effects on endothelial cells (VEGFR2, ERK1/2) and fibroblasts (GHR) are documented, no published study has examined its direct effects on osteoblasts, osteoclasts, or bone marrow-derived mesenchymal stem cells. The mechanistic case for bone healing is built entirely on inference from other cell types.
Publication bias. Nearly all published BPC-157 studies report positive results. The absence of negative findings in the literature raises questions about whether null results exist but remain unpublished.
The broader healing pattern
Seiwerth et al. (2018) reviewed BPC-157 against standard angiogenic growth factors (EGF, FGF, VEGF) across gastrointestinal, tendon, ligament, muscle, and bone healing.[3] Their central claim: BPC-157 was consistently effective across all tested injury models using the same administration regimens, while EGF, FGF, and VEGF showed inconsistent results and typically required complex carrier and delivery systems.
This cross-tissue consistency is part of what makes BPC-157 both intriguing and difficult to evaluate. A peptide that heals gut ulcers, skin wounds, tendons, ligaments, muscles, and bones through a shared angiogenic mechanism would represent something genuinely novel in pharmacology. It would also be extraordinary, and extraordinary claims require extraordinary evidence.
For bone specifically, the evidence is thinner than for other tissues. BPC-157's tendon healing evidence spans multiple studies across different tendon models and injury types. Its muscle recovery evidence includes several distinct injury models. But for bone fracture healing, the entire direct evidence base rests on one rabbit study from 1999. The periodontitis study (Keremi 2009) adds a bone resorption dimension, and the Achilles detachment study (Krivic 2006) involves the tendon-bone interface. Neither directly tests fracture repair.
The fibroblast and collagen synthesis research may eventually connect to bone healing, since osteoblasts share signaling pathways with fibroblasts. The relationship between BPC-157 and other peptides being studied for bone density, such as collagen peptides, may point toward complementary approaches to skeletal health research. But until independent laboratories test BPC-157 in fracture models, and until human data of any quality exists, the bone healing narrative remains a hypothesis supported by a single animal experiment and a plausible molecular mechanism.
The Bottom Line
BPC-157 healed segmental bone defects in rabbits with efficacy comparable to bone marrow grafts, and separate studies demonstrate plausible mechanisms through VEGFR2-mediated angiogenesis, anti-inflammatory effects, and growth hormone receptor upregulation. Zero human bone fracture data exist. The evidence base is limited to preclinical work predominantly from a single research group, and independent replication of bone-specific effects has not been published.